ranges between 5 and 25%, depending on the kind of chronic heart failure populations studied (5) . Previously the wasting mechanisms were only vaguely understood. Hypermetabolism, anorexia and hypoxia have been suggested (6) . Bowel oedema was thought to impair nutrient absorption (7) . These proposed mechanisms are probably still relevant for the development of cardiac cachexia. The recent studies of Dr Anker and others have rmly established the strong association between proin ammatory cytokine activity, e.g. TNF and interleukin-6 (IL-6), and cardiac cachexia, although the mechanisms triggering in ammation are still not understood, as depicted by Dr Anker.
Therapeutic implications
The new insights into the systemic character of many organ diseases open pathways for future treatment strategies, not only in chronic heart failure, but also in other organ disorders complicated by catabolism due to secondary systemic in ammation. Until today treatment of chronic heart failure has been directed towards the negative haemodynamic effects of the disorder. The recent introduction of the angiotensin-convertin g enzyme (ACE) inhibitors, e.g. captopril, represents a great achievement in heart failure treatment. The benecial effects of ACE inhibitors have mainly been attributed to diminished cardiac workload by interference with the renin -angiotensin-aldosterone system. However, ACE inhibitors have subsequently been shown to possess anti-in ammatory properties (8) and it may be speculated that some of the bene cial effects of ACE inhibitors are conferred by such activities. For example, it was recently shown that reduced cardiac septum thickness after enalapril treatment in congestive heart failure patients was related to decreased inammation (9) . Anti-TNF treatment, as accomplished by TNF receptor blockade (etanercept) or antibody treatment against TNF (in iximab), has recently been shown to be effective in primary in ammatory disorders such as rheumatoid arthritis (10) and in ammatory bowel disease (11) . However, such treatments have so far not been proven effective in cardiac congestion. A possible reason for the con icting results may be that in, for example, chronic heart failure in ammation may be viewed as a two-edged adaptive response to the disease with both positive and negative in uences on the disease progression. TNF blocking therapy may, under such conditions, abolish not only the negative effects of in ammation. Other cytokine modulating substances, e.g. megestrol acetate, thalidomide and pentoxifyllin, are being evaluated in various clinical conditions with wasting. Results are promising but still inconclusive (12, 13) . The current challenge may be to determine the adequate level of in ammatory modi cation and to nd the most appropriate patients to treat by anti-in ammatory means.
Research efforts such as those presented by Dr Anker and his colleagues will hopefully in the near future lead to pharmacological treatments that may complement and facilitate more conventional nutritional treatment in wasting disorders, thus contributing to the pursuit of sustaining malfunctioning catabolic patients to cope better with daily living.
